genedrive plc (GDR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, genedrive plc (GDR) has a cash flow conversion efficiency ratio of -1.421x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-2.04 Million ≈ $-248.70 USD) by net assets (GBX1.44 Million ≈ $174.96 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check genedrive plc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
genedrive plc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how genedrive plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See genedrive plc (GDR) shareholders funds for net asset value and shareholders' equity analysis.
genedrive plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of genedrive plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
I.Ceram SA
PA:ALICR
|
0.094x |
|
LMS Capital Plc
LSE:LMS
|
-0.042x |
|
Fulcrum Metals PLC
LSE:FMET
|
N/A |
|
MOBILITYONE LTD LS -025
F:31M
|
N/A |
|
Meyer Burger Tech AG
SW:MBTN
|
-0.961x |
|
Rua Life Sciences PLC
LSE:RUA
|
-0.023x |
|
Kukbo Co. Ltd.
KO:001140
|
0.946x |
|
LANEBURY GROWTH CAP.
F:L01
|
-0.197x |
Annual Cash Flow Conversion Efficiency for genedrive plc (2006–2025)
The table below shows the annual cash flow conversion efficiency of genedrive plc from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see genedrive plc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | GBX1.44 Million ≈ $174.96 |
GBX-5.10 Million ≈ $-620.64 |
-3.547x | -404.51% |
| 2024-06-30 | GBX5.36 Million ≈ $652.04 |
GBX-3.77 Million ≈ $-458.46 |
-0.703x | +62.00% |
| 2023-06-30 | GBX2.04 Million ≈ $248.33 |
GBX-3.78 Million ≈ $-459.43 |
-1.850x | -125.18% |
| 2022-06-30 | GBX5.61 Million ≈ $682.70 |
GBX-4.61 Million ≈ $-560.90 |
-0.822x | +43.07% |
| 2021-06-30 | GBX3.59 Million ≈ $437.04 |
GBX-5.18 Million ≈ $-630.74 |
-1.443x | -227.33% |
| 2020-06-30 | GBX-3.34 Million ≈ $-406.62 |
GBX-3.79 Million ≈ $-460.89 |
1.133x | -22.43% |
| 2019-06-30 | GBX-2.48 Million ≈ $-301.50 |
GBX-3.62 Million ≈ $-440.57 |
1.461x | +39.82% |
| 2018-06-30 | GBX-2.44 Million ≈ $-296.51 |
GBX-2.55 Million ≈ $-309.90 |
1.045x | +295.77% |
| 2017-06-30 | GBX3.44 Million ≈ $418.67 |
GBX-1.84 Million ≈ $-223.51 |
-0.534x | +42.77% |
| 2016-06-30 | GBX3.75 Million ≈ $456.63 |
GBX-3.50 Million ≈ $-425.97 |
-0.933x | -169.33% |
| 2015-06-30 | GBX9.54 Million ≈ $1.16K |
GBX-3.31 Million ≈ $-402.24 |
-0.346x | -244.58% |
| 2014-06-30 | GBX10.86 Million ≈ $1.32K |
GBX-1.09 Million ≈ $-132.86 |
-0.101x | -97.99% |
| 2013-06-30 | GBX12.05 Million ≈ $1.47K |
GBX-612.00K ≈ $-74.46 |
-0.051x | -66.01% |
| 2012-06-30 | GBX8.86 Million ≈ $1.08K |
GBX-271.00K ≈ $-32.97 |
-0.031x | +72.95% |
| 2011-06-30 | GBX6.18 Million ≈ $752.17 |
GBX-699.00K ≈ $-85.05 |
-0.113x | +8.53% |
| 2010-06-30 | GBX5.78 Million ≈ $703.75 |
GBX-715.00K ≈ $-86.99 |
-0.124x | -118.01% |
| 2009-06-30 | GBX2.76 Million ≈ $335.81 |
GBX1.89 Million ≈ $230.45 |
0.686x | +256.66% |
| 2008-06-30 | GBX2.58 Million ≈ $314.15 |
GBX-1.13 Million ≈ $-137.61 |
-0.438x | -41.49% |
| 2007-06-30 | GBX2.60 Million ≈ $315.98 |
GBX-804.00K ≈ $-97.82 |
-0.310x | +61.17% |
| 2006-06-30 | GBX1.09 Million ≈ $133.23 |
GBX-873.00K ≈ $-106.22 |
-0.797x | -- |
About genedrive plc
genedrive plc engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications. The company provides Genedrive system, rapid nucleic acid thermocycler and fluorescence signal detection system for target discrimination used for qualitative in vitro molecular diagnos… Read more